A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
A Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Clinical Trials Information Group Officer
- Telefonní číslo: 86-0311-69085587
- E-mail: ctr-contact@cspc.cn
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- 1. Age: 18-75 years (Whichever is on the day of signing the informed consent form).
2. Subjects have histologically or cytologically confirmed breast cancer at unresectable,recurrent/metastatic stage, with the requirements below based on the most recent pathological report:
- HER2-negative confirmed by histological or cytological testing;
- Pathological report is available to confirm HR status.
- 3. Assessed by the Investigator as suitable for single-agent docetaxel therapy.
- 4. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
- 5. Has adequate organ and system functions within 7 days prior to the first dose.
- 6. Eastern Cooperative Oncology Group performance status of 0 or 1.
- 7. Expected survival ≥ 3 months.
Exclusion Criteria:
- 1. Has received prior taxane-containing single-agent or combination regimens, and have disease progression during salvage therapy for unresectable locally advanced or metastatic breast cancer (has received at least 2 cycles), or developed recurrent-metastatic disease within 12 months following adjuvant therapy.
- 2. History of severe allergy or hypersensitivity reactions (Grade ≥3 per NCI-CTCAE Version 6.0) to human serum albumin or docetaxel and/or contraindications thereto, or history of severe allergy and/or contraindications to glucocorticoids.
- 3. Untreated active brain metastases (including brain or leptomeningeal metastases). Subjects with treated brain metastases may be enrolled if lesions are stable without evidence of new or enlarging pre-existing brain metastases.
- 4. With a history of other primary malignant tumors within 5 years before administration.
- 5. Presence of serous cavity effusion requiring drainage or diuretic therapy within 2 weeks prior to the first dose.
- 6. Severe neurological diseases (e.g., epilepsy, dementia, etc.) and Grade ≥2 peripheral neuropathy.
- 7. Receipt of systemic glucocorticoid therapy within 14 days prior to the first dose.
- 8. Current clinically significant abnormal interstitial lung disease.
- 9. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to the first dose.
- 10. Has arterial or venous thromboembolism (e.g., lower-extremity deep vein thrombosis, lower-extremity arterial embolism, pulmonary embolism, etc.) within 6 months prior to the first dose. Stable thrombus is permitted for enrollment if the Investigator assesses no associated cardiovascular risk.
- 11. Severe chronic or active infection requiring intravenous antibacterial, antifungal, or antiviral therapy within 2 weeks prior to the first dose.
- 12. Has undergone major visceral organ surgery (excluding puncture biopsy or infusion device implantation) within 4 weeks prior to the first dose, or who require major visceral organ surgery during the study period.
- 13. Receipt of chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or other investigational study drug within 4 weeks or 5 half-lives prior to the first dose (whichever is shorter, with a minimum of 2 weeks); receipt of radiotherapy within 2 weeks prior to the first dose; receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose.
- 14. Toxicities from all prior anti-tumor therapies have not recovered to Grade 1 or less prior to the first dose.
- 15. Has received powerful CYP3A4 inhibitor or inducer within 2 weeks before the first dose.
- 16. Has active hepatitis B infection, hepatitis C infection, positive HIV antibody, or active syphilis.
- 17. Concurrent participation in another interventional clinical study.
- 18. Any other conditions that, in the Investigator's opinion, render the participant unsuitable for participation in this clinical trial.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: HB1801
|
HB1801, 100 mg/m² in Cycle 1, 75 mg/m² starting from Cycle 2, once every 3 weeks (Q3W), intravenous infusion over 60 minutes.
|
|
Experimentální: Docetaxel (Taxotere®)
|
Docetaxel (Taxotere®), 75 mg/m², Q3W, intravenous infusion over 60 minutes.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free Survival (PFS)
Časové okno: up to approximately 2 years after the first enrollment
|
PFS was defined as the time from the date of randomization to the date of progressive disease (as per RECIST v1.1) or death due to any cause.
|
up to approximately 2 years after the first enrollment
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Objective Response Rate (ORR) assessed per RECIST v1.1
Časové okno: up to approximately 2 years after the first enrollment
|
ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with complete response (CR) or partial response (PR).
|
up to approximately 2 years after the first enrollment
|
|
Duration of Response (DOR)
Časové okno: up to approximately 2 years after the first enrollment
|
DOR by investigator assessment according to RECIST 1.1 in participants with CR or PR, defined as the time from the first documented CR/PR to PD or death.
|
up to approximately 2 years after the first enrollment
|
|
Disease Control Rate (DCR)
Časové okno: up to approximately 2 years after the first enrollment
|
DCR by investigator assessment according to RECIST 1.1, defined as the percentage of participants with CR, PR, or stable disease (SD) lasting at least 6 weeks.
|
up to approximately 2 years after the first enrollment
|
|
Overall Survival (OS)
Časové okno: up to approximately 2 years after the first enrollment
|
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from study therapy or received another subsequent anticancer therapy.
|
up to approximately 2 years after the first enrollment
|
|
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Časové okno: up to approximately 2 years after the first enrollment
|
up to approximately 2 years after the first enrollment
|
|
|
Plasma concentration of docetaxel (free and total)
Časové okno: After completion of infusion administration on Day 1 of Cycle 1
|
After completion of infusion administration on Day 1 of Cycle 1
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- HB1801-017
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .